. PHOTO THERAPEUTICS LTD Ka 50 Me AUG 9 - 2005
510(k) Summary of Safety and Effectiveness for the
Photo Therapcutics Limited Omnilux Plus
‘Lhis 510(k) Summary of Safcty and Effectiveness is being submitted in accordance with
the requirements of the SMDA 1990 and 21 CFR 807.92.
1. Gencral Information

Submitter: Pholo Therapeutics Limited
Station House
Stamford New Road
Altrincham _
Cheshire WA14 1EP
United Kingdom

Contact Person: Steve Hutson
Director of Engineering and Regulatory
Affairs
Photo Therapeutics Limited
Station House
Stamford New Road
Altnnecham
Cheshire WA14 1EP a
United Kingdom
T: +44 161 925 5615
F: +44 16] 925 5628

Summary Preparation Date: December 10th, 2004

2. Names

Device Name: Omnilux Revive and Omnilux Plus
Combination

Classification Name: Omnilux Revive - Laser Instrument,
Surgical Powered - Genera! and Plastic
Surgery - Class Il, 79-GEX
Although this device is not a lascr, the
manufacturer thinks this is the closest
applicable classification name.
Ommnilux Plus — Lamp, Infrared - Physical
Medicine - Class Il, 89-iLY, 890.5500

tre PHOTO THERAPEUTICS LTD ~ : bofOAle

3. Predicate Devices
Predicate devices for the Omnilux Revive and the Omnilux Plus were detailed in ,
K030426 and 510K submission K043317 respectively. .

4. Device Description
The Omnilux Revive and Omnilux Plus arc two sources of high spectral punty.
They provide uniform or “hot-spot” frec illumination. The outputs are pre-tuned
to one wavelength with a narrow spectral bandwidth. The output of the Omnilux
Revive is 633 + 5 nm, and the output of the Ommilux Plus is 830 + 5 nm. The base
unit contains the power supplies and the control unit. Attached to the base unit __
are three folding arms. The LED head can be attached to the end of the arms and
then positioned for patient treatment. The control unit consists of an LCD and
keyboard together with the control clectronics. The user interface software allows
the operator to access and control all device functions.

5. Indications for Use
The Omnilux Revive and Omnilux Plus Combination is intended lo emit energy
in the red and infra-red region of the spectrum for use in dermatology for the
treatment of periorbital wrinkles.

6. Performance Data
Based upon an analysis of the overall performance characteristics for the device,
Photo Therapeutics Limited bclicves that no significant differences exist betwecn
the Omnilux Revive and the Omnilux Plus Combination, the previously approved
Omnilux Revive (K030426) and the Omnilux Plus (which is the subject of 510K
submission K043317). Therefore, the Omnilux Revive and Omnilux Plus
Combination raiscs no new issues of safety or effectivencss.

i 4 DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
%e, rc
mot Food and Drug Administration

AUG 9 - 2005 9200 Corporate Boulevard
Rockville MD 20850
Mr. Steve Hutson
Director of Engineering and Regulatory Affairs
Photo Therapeutics Limited ets a
Station House, Stamford New Road
Altrincham Cheshire
WA 14 LEP
United Kingdom
Re: K050216
: Trade/Device Name: Omnilux Revive and Omnilux Plus Combination
Regulation Number: 21 CFR 878.4810
Regulation Name: Laser surgical instrument for use in general and plastic surgery
and in dermatology
Regulatory Class: II
Product Code: GEX
Dated: June 16, 2005
Received: June 22, 2005
Dear Mr. Hutson:
We have reviewed your Section 510(k) premarket notification of intent to market the device
referenced above and have determined the device is substantially equivalent (for the indications
for use stated in the enclosure) to legally marketed predicate devices marketed in interstate
commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to
devices that have been reclassified in accordance with the provisions of the Federal Food, Drug,
and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA).
You may, therefore, market the device, subject to the general controls provisions of the Act. The
general controls provisions of the Act include requirements for annual registration, listing of
devices, good manufacturing practice, labeling, and prohibitions against misbranding and
adulteration.
If your device is classified (see above) into either class II (Special Controls) or class II] (PMA), it
may be subject to such additional controls. Existing major regulations affecting your device can
be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may
publish further announcements concerning your device in the Federal Register.
Please be advised that FDA’s issuance of a substantial equivalence determination does not mean
that FDA has made a determination that your device complies with other requirements of the Act
ort any Federal statutes and regulations administered by other Federal agencies. You must
comply with all the Act’s requirements, including, but not limited to: registration and listing (21
CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic
product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2- Mr. Steve Hutson
This letter will allow you to begin marketing your device as described in your Section 510(k)
premarket notification. The FDA finding of substantial equivalence of your device to a legally
marketed predicate device results in a classification for your device and thus, permits your device
to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please
contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled,
"Misbranding by reference to premarket notification” (21CFR Part 807.97). You may obtain
other general information on your responsibilities under the Act from the Division of Small
Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or
(301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain. html

Sincerely yours,

(forbs Pract

Mark N. Melkerson

Acting Director

Division of General, Restorative

and Neurological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

Device Nume Omunilux Revive and Omnilux Plus Combination
Indications for Use: kos CALE
: The Omnilux Revive and Omnilux Plus Combination i$ intended to emit energy in the ~~
red and infra-red region of the spectrum for use in dermatology for the treatment of
periorbital wrinkles.
Prescription Use x AND/OR Over The Counter Use
(Per 21 CFR 801,109)
(PLEASE DO NOT WRITE BELOW. THIS LINE — CONTINUE ON ANOTHER PAGE
IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
f y ( key o my”
AA 5

Arabi puchuid-fy Nove Mel os

Division Sign-Off)

Division of General, Restorative

and Neurological Devices

<10G0 Number KOS

